ESR1 and breast cancer: Androgen receptor therapy considered in breast cancer includes two main strategies: agonist administration in ERα+ cancers and antagonist administration in AR+ TNBC (the ‘molecular apocrine disease’), in this case the evaluated drugs include bicalutamide, enzalutamide, abiraterone acetate and orteronel [131].